Back HIV/AIDS

HIV / AIDS

4. PrEP Use Widens, But Disparities Remain

Pre-exposure prophylaxis (PrEP) was again a major HIV story in 2016. The latest figures from a pharmacy survey by Gilead Sciences showed that more than 79,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for HIV prevention, but the survey does not include all PrEP providers and most experts think this estimate is low.

alt

5. HIV Prevention for Women

Use of Truvada for pre-exposure prophylaxis (PrEP) is highly effective and is now widely used among gay men, but biomedical HIV prevention for women has lagged behind.

alt

IDWeek 2016: Comorbidities Are Common and Rising Among People with HIV

People living with HIV are increasingly experiencing a range of non-AIDS-related comorbidities as the population ages, including cardiovascular disease, kidney impairment, and bone loss leading to fractures, according to research presented at the recent IDWeek 2016 meeting in New Orleans.

alt

6. HIV Incidence Falls, But Not for Young Black Gay Men

New data show that while new HIV infections and diagnoses have decreased overall, they remain high for some population groups -- especially young black gay men in the U.S.

UNAIDS Special Session Looks at HIV and Aging, New Report Examines Long-Term AIDS Survival

A UNAIDS Programme Coordinating Board meeting on December 8 addressed the challenges related to an aging population with HIV worldwide. In related news, activist Matt Sharp recently released a new report on long-term survivors living with HIV/AIDS.

alt

UCSF/amfAR HIV Cure Summit Reviews Progress in Cure-Related Research

Researchers at the amfAR Institute for HIV Cure Research at the University of California at San Francisco (UCSF) presented an update on their latest cure-related work at a World AIDS Day summit on December 1. This multidisciplinary effort aims to understand HIV reservoirs within the body and ultimately to control or eliminate the virus.alt

Advocates Call for More Research on Immune-Enhancing Therapies for People with HIV

HIV/AIDS activists recently issued a call for expanded research to accelerate the development of immune-enhancing therapies for HIV-positive immunological non-responders -- people who achieve viral suppression on antiretroviral therapy but do not see their CD4 T-cell count return to near-normal levels, and therefore remain at increased risk of illness and death.

alt